Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Single-blind Study to Assess the Safety, Tolerability, and Pharmacokinetics of Benralizumab Administered as Single Subcutaneous Dose in Healthy Chinese Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Single-blind Study to Assess the Safety, Tolerability, and Pharmacokinetics of Benralizumab Administered as Single Subcutaneous Dose in Healthy Chinese Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Churg-Strauss syndrome; Eosinophilic gastroenteritis; Hypereosinophilic syndrome; Nasal polyps; Rhinosinusitis
  • Focus Adverse reactions
  • Sponsors AstraZeneca

Most Recent Events

  • 29 Aug 2019 Status changed from active, no longer recruiting to completed.
  • 28 Jun 2019 Planned End Date changed from 9 Aug 2019 to 7 Aug 2019.
  • 28 Jun 2019 Planned primary completion date changed from 9 Aug 2019 to 7 Aug 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top